BridgeBio starts dosing in phase 1/2 trial of BBP-398, Opdivo combo for solid tumors

Modern Medicine Research Laboratory: Diverse Team of Multi-Ethnic Young Scientists Passes Samples in Petri Dish. Advanced Lab with High-Tech Equipment, Microbiology Researchers Design, Develop Drugs


BridgeBio Pharma (NASDAQ:BBIO) said the first patient with non-small cell lung cancer (NSCLC) was dosed in a phase 1/2 trial of BBP-398 with Bristol Myers Squibb’s (NYSE:BMY) Opdivo (nivolumab) to treat advanced solid tumors with KRAS mutations.

KRAS mutations occur

Source link